Key result
Five-miRNA panel detects HFrEF with near-perfect diagnostic accuracy at ~1.00 AUC.
Why the study?
Few studies have compared the performance of reported miRNAs as biomarkers for HFrEF in a high-risk population.
Does a panel of circulating miRNAs accurately diagnose HFrEF compared to hypertensive controls without heart failure?
Case-Control (n=60)
No
Does a panel of circulating miRNAs accurately diagnose HFrEF compared to hypertensive controls without heart failure?
A panel of five circulating miRNAs demonstrates excellent diagnostic accuracy for identifying HFrEF, suggesting potential utility as a biomarker alternative or adjunct to NT-proBNP.
Answers are grounded in this paper and cite their sources.
This miRNA panel may aid HFrEF diagnosis; extends single-miRNA studies but leaves clinical utility open pending prospective validation.
Background: Few studies have compared the performances of those reported miRNAs as biomarkers for heart failure with reduced EF (HFrEF) in a population at high risk. The purpose of this study is to investigate comprehensively the performance of those miRNAs as biomarkers for HFrEF. Methods: By using bioinformatics methods, we also examined these miRNAs' target genes and possible signal transduction pathways. We collected serum samples from patients with HFrEF at Zhongshan Hospital. Receiver operating characteristic (ROC) curves were used to evaluate the accuracy of those miRNAs as biomarkers for HFrEF. miRWALK2.0, Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed to predict the target genes and pathways of selected miRNAs. Results: The study included 48 participants, of whom 30 had HFrEF and 18 had hypertension with normal left ventricular ejection fraction (LVEF). MiR-378, miR-195-5p were significantly decreased meanwhile ten miRNAs were remarkably elevated (miR-21-3p, miR-21-5p, miR-106-5p, miR-23a-3p, miR-208a-3p, miR-1-3p, miR-126-5p, miR-133a-3p, miR-133b, miR-223-3p) in the serum of the HFrEF group. Conclusion: The combination of miR 133a-3p, miR 378, miR 1-3p, miR 106b-5p, and miR 133b has excellent diagnostic performance for HFrEF, and there is a throng of mechanisms and pathways by which regulation of these miRNAs may affect the risk of HFrEF.
No takes yet. Share an insight, caveat, or question.
Kuai et al. (2024) conducted a case-control in Heart failure with reduced ejection fraction (HFrEF) (n=60). Circulating miRNA combination (miR 133a-3p, miR 378, miR 1-3p, miR 106b-5p, and miR 133b) vs. Hypertensive controls (NoHF) was evaluated on Diagnostic performance (Area Under the ROC Curve) for HFrEF (AUC 0.997, p=<0.01). A combination of five circulating miRNAs (miR 133a-3p, miR 378, miR 1-3p, miR 106b-5p, and miR 133b) demonstrated excellent diagnostic performance for identifying HFrEF, yielding an AUC of 0.997.
Synapse has enriched 10 related papers. Consider them for comparative context: